On January 9, 2024 ConcertAI and Caris Life Sciences (Caris) reported a multi-year partnership to support AbbVie’s precision medicine-driven research and development efforts, and clinical trial optimization in oncology (Press release, Caris Life Sciences, JAN 9, 2024, View Source [SID1234639172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement will allow AbbVie to leverage Caris’ expansive real-world, multi-modal database in oncology and ConcertAI’s collection of research-grade clinical data across a wide range of cancers, to guide the development of novel therapies for patients most likely to benefit. The agreement will also allow AbbVie to utilize ConcertAI and Caris’ clinical network and laboratory capabilities combined with AI/ ML learning to optimize oncology clinical trials and patient enrollment.

"We are continuing to expand our drug discovery and development efforts in oncology, with the ultimate goal to deliver transformative treatments to cancer patients," said Tom Hudson, SVP, Chief Scientific Officer, Global Research at AbbVie. "This agreement marks a key step in that direction, as it represents a union of cutting-edge technology and pioneering science, leveraging the power of big data, artificial intelligence and machine learning to propel our efforts in the fight against cancer."

"This partnership furthers our goals of enabling causal biological inferences, where multi-modal data can be integrated with AI/ML-based approaches in drug discovery, translation and development, to accelerate oncology pipelines, and allow our biopharma partners to discover and deliver better medicines faster," said Jeff Elton, Ph.D., CEO of ConcertAI.

"We are thrilled to work with AbbVie, a leader in driving innovation in drug development, to support their work in oncology," said Dr. George W. Sledge, Jr., Chief Medical Officer of Caris. "This work may help identify novel targets and mechanisms, and key levers to drive clinical trial excellence to support AbbVie’s oncology portfolio."